We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 30, 2020

Sacituzumab Govitecan in Previously Treated Hormone Receptor–Positive/HER2-Negative Metastatic Breast Cancer

Annals of Oncology


Additional Info

Annals of Oncology
Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results From a Phase I/II, Single-Arm, Basket Trial
Ann. Oncol 2020 Dec 01;31(12)1709-1718, K Kalinsky, JR Diamond, LT Vahdat, SM Tolaney, D Juric, J O'Shaughnessy, RL Moroose, IA Mayer, VG Abramson, DM Goldenberg, RM Sharkey, P Maliakal, Q Hong, T Goswami, WA Wegener, A Bardia

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading